According to a market report by Lucintel, the future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are the increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.
A more than 150-page report to understand trends, opportunity and forecast in next generation cancer diagnostics market to 2030 by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.
Download sample by clicking on next generation cancer diagnostics market
North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.
Janssen Pharmaceuticals, Illumina, Novartis, F. Hoffmann-La Roche, Koninklijke Philips, QIAGEN, Agilent Technologies, Abbott, Thermo Fisher Scientific, GE HealthCare are the major suppliers in the next generation cancer diagnostics market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected] To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Laboratory Animal Housing Plastic Cage Market
Medical Adult Flexible Laryngoscope Market
Medical Light Guide Rod Market
Multi-unit Abutment Market
Mycotoxin ELISA Rapid Test Kit Market